Aminocaproic Acid
Aminocaproic Acid is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Aminocaproic Acid; Generic name: AMINOCAPROIC ACID; Drug class: Antifibrinolytic Agent [EPC].
| Brand name | Aminocaproic Acid |
|---|---|
| Generic name | AMINOCAPROIC ACID |
| Drug class | Antifibrinolytic Agent [EPC] |
| Manufacturer | Apozeal Pharmaceuticals Inc. |
| Used for | INDICATIONS AND USAGE Aminocaproic acid is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required. Fibrinolytic bleeding may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures) and portacaval shunt; hematological disorders such as amegakaryocytic thrombocytopenia (accompanying aplastic anemia); acute and life-threatening abruptio placentae; hepatic cirrhosis; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix. Urinary fibrinolysis, usually a normal physiol |
| Dosage | DOSAGE AND ADMINISTRATION An identical dosage regimen may be followed by administering aminocaproic acid oral solution as follows: For the treatment of acute bleeding syndromes due to elevated fibrinolytic activity, it is suggested that 20 milliliters of aminocaproic acid oral solution (5 g) be administered during the first hour of treatment, followed by a continuing rate of 5 milliliter of aminocaproic acid oral solution (1.25 g) per hour. This method of treatment would ordinarily be continued |
| Warnings | WARNINGS In patients with upper urinary tract bleeding, aminocaproic acid administration has been known to cause intrarenal obstruction in the form of glomerular capillary thrombosis or clots in the renal pelvis and ureters. For this reason, aminocaproic acid should not be used in hematuria of upper urinary tract origin, unless the possible benefits outweigh the risk. Subendocardial hemorrhages have been observed in dogs given intravenous infusions of 0.2 times the maximum human therapeutic dose |
| Active ingredient(s) | AMINOCAPROIC ACID |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15aa2f36-ccc6-431a-99a2-45d812ef4bbf |